Thomas J. Schall insider trades
Open-market stock purchases and sales by Thomas J. Schall, Director at Immuneering Corp, from SEC Form 4 filings since Feb 27, 2012.
Track record: 100% of 3 scored buys are up 5% or more since purchase, averaging +55%.